Atara Biotherapeutics, Inc. - 8-K Filing
Atara Biotherapeutics reports Q3 2026 revenue of $1.2M and net loss of $2.2M, noting a PDUFA date of March 31, 2027, for tab-cel BLA resubmission. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ATRA